Retraction and republication—Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study – The Lancet

Retraction and republication—Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study  The Lancet


Posted

in

by

Tags:

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *